What is ZSTK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ZSTK.

Stock Ratings / Health Care / ZSTK / options

ESYN (38) COSM (29) NUS (50) MEDS (28) ⌘ Pro Terminal →

ZeroStack Corp. (ZSTK) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is ZSTK trading relative to its 50-day, 200-day, and 52-week technical levels?

ZSTK last traded at $2.77 (-0.36% on volume of 6,681 shares), positioning the stock -35.88% below its 50-day simple moving average ($4.32) and -46.00% below its 200-day simple moving average ($5.13). Across its 52-week range of $1.32 to $15.04, ZSTK sits at the 10.6% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.42 to $3.12).

$2.77 -0.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.76

ZeroStack Corp. (ZSTK) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $60.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZSTK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.77 (-0.36% 1D, market cap $60.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #932 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZSTK compare to ESYN and COSM in the Health Care sector?

▼

Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $52.0M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZSTK?

▼

Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.76 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZSTK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY ZSTK SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (40% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (20% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 28.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.37-15.1% Next Q

Q2 (-2Q)

Grade E$3.71-18.6% Next Q

Q3 (-1Q)

Grade E$3.02-8.3% Next Q

Current

Grade E$2.77-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZSTK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZSTK currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.32) and Max Pain ($2.91) forces dealer call-delta covering toward $15.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZSTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZSTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ZSTK)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ZSTK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZSTK)

✓Walkthrough of ZSTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZSTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.27%📐 HORIZONTAL RANGE

2026-11-03O $2.93H $2.93L $2.77C $2.77VOL 3.9K

SUP: $-1.99SMA50: $4.32SMA200: $5.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZSTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZSTK Butterfly Map → + Track ZSTK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ZSTK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZSTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZSTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZSTK)

Health Care Rank #932 of 1016 ⚔️ ESYN vs ZSTK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZSTK vs. ESYN, COSM, NUS, MEDS)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ZeroStack Corp. (ZSTK) ranks #932 by composite RQD confidence (25/100, grade E) and #717 by equity capitalization ($60.7M). Within this direct 5-issuer industry benchmark cohort, ZSTK leads on earnings valuation at N/A trailing P/E, while NUS leads on capital efficiency and profitability with 6.7% ROIC and 69.4% gross margin. NUS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ZSTK at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZSTK ACTIVE ZeroStack Corp.	E	25/100	—	4.6%	-35.0%	-0.36%	$60.7M	Benchmark Subject
ESYN EnerSyn Global Inc.	D-	38/100	—	53.0%	-35.0%	-5.14%	$52.0M	/esyn-vs-zstk →
COSM Cosmos Health Inc.	E	29/100	—	12.1%	-35.0%	+0.33%	$31.0M	/cosm-vs-zstk →
NUS Nu Skin Enterprises Inc.	D	50/100	—	69.4%	6.7%	+2.80%	$226.3M	/nus-vs-zstk →
MEDS DataMeds AI Inc.	E	28/100	—	-27.5%	-35.0%	-4.69%	$9.3M	/meds-vs-zstk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001790169 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ZeroStack Corp. (ZSTK) reported GAAP revenue of $35.7M (-0.5% vs. FY2024 revenue of $35.9M , and -53.1% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$8.7M, and free cash flow of -$8.8M (-70.4% YoY). On the balance sheet, ZSTK closed FY2025 with $130.2M in total assets against $50.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$35.7M	$0	-$8.7M	-$8.8M	$130.2M	$50.8M
FY2024 (FY)	2024-12-31	$35.9M	-$15.9M	-$5.0M	-$5.2M	$26.2M	$0
FY2023 (FY)	2023-12-31	$76.1M	-$57.0M	-$8.4M	-$8.4M	—	—

3. ZSTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZSTK compare to ESYN and COSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZSTK?

Where is ZSTK trading relative to its 50-day, 200-day, and 52-week technical levels?

ZSTK last traded at $2.77 (-0.36% on volume of 6,681 shares), positioning the stock -35.88% below its 50-day simple moving average ($4.32) and -46.00% below its 200-day simple moving average ($5.13). Across its 52-week range of $1.32 to $15.04, ZSTK sits at the 10.6% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.42 to $3.12).

Direct Sub-Reports: ZSTK RQD Cockpit ZSTK 12M Forecast ZSTK Earnings & Move ZSTK Dividends & DRIP ZSTK Insiders & 13F ZSTK Whale Options ZSTK Profit Sankey ZSTK News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

ZSTK — ZeroStack Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ZeroStack Corp. (ZSTK) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.77 (-0.36% 1D, market capitalization $60.7M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 4.6%, operating margin of -60.0%, and free cash flow yield of -13.77%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of 0.72x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ZeroStack Corp. (ZSTK) is a NASDAQ-listed operating company in the Other Pharmaceuticals industry (Health Care sector) with an equity market capitalization of $60.7M. The business operates with a gross margin of 4.6%, an operating margin of -60%, and a return on invested capital (ROIC) of -35% (free cash flow yield of -13.77%). Within the Other Pharmaceuticals peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ZeroStack Corp. (ZSTK) reported $35.7M in annual revenue (up from $35.9M in FY2024, -0.5% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($76.1M revenue, -$57.0M net income) through FY2025, ZSTK scaled operating cash flow to -$8.7M and free cash flow to -$8.8M, backed by $130.2M in total assets against $50.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.77% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.32 – $15.04 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Other Pharmaceuticals (Health Care), ZSTK carries a macro regime beta of 1.00 and gross margin of 4.6%.

Key Question #1: Can ZSTK sustain or expand its -60.0% operating margin and -35.0% ROIC against Other Pharmaceuticals peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $35.7M and free cash flow of -$8.8M, how will capital allocation balance growth reinvestment against $50.8M in total debt?
Key Question #3: How sensitive is ZSTK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ZSTK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ZeroStack Corp. (ZSTK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZSTK Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 20h ago

ZeroStack Corp. Estimates – NASDAQ:ZSTK

TradingView report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 23h ago

Which of rYojbaba (NASDAQ:RYOJ), Profusa (NASDAQ:PFSA), Beam Global (NASDAQ:BEEM), ZeroStack (NASDAQ:ZSTK) or Presidio Property Trust (NASDAQ:SQFT) Fell 7% to 10% in Pre-Market?

kalkine.ca report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

ZeroStack Corp. (ZSTK) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering ZeroStack Corp. (ZSTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock moved upwards

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 69d ago

Zerostack’s Crypto Holdings Top $1 Billion

Zerostack’s (NASDAQ: $ZSTK) cryptocurrency holdings have reached $1.06 billion U.S.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 75d ago

Top Midday Gainers

ZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 76d ago

ZeroStack Announces Completion of Continuance to Texas

Dallas, Texas--(Newsfile Corp. - August 18, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) ("ZeroStack" or the "Company"), the first Nasdaq-listed, AI-focused asset management company, today announced that, effective August 18,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 117d ago

ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companies

Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured pharmac

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZSTK Bull vs. Bear Conversation Board — What's Your Call at $2.77?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZSTK 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $3.50 (+25.9%)

📌 Pinned Debate

The stock trades at a $63.9M market cap with a 4.6% gross margin and a 0% dividend yield, leaving room for upside if cash generation re

Long ZSTK at $2.78 targeting $3.50. The stock trades at a $63.9M market cap with a 4.6% gross margin and a 0% dividend yield, leaving room for upside if cash generation recovers.. Institutional whale score is 3/20 and the risk/reward vs. the $1.32 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Other Pharmaceuticals. If gross margin (4.6%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.28 (-18.0%)

Spot @ $2.78

ROIC of -35%, FCF yield of -13.77%, and a Piotroski F of 2 out of 9 signal weak cash returns and forensic balance-sheet risk.

Fading this rally in ZSTK at $2.78. ROIC of -35%, FCF yield of -13.77%, and a Piotroski F of 2 out of 9 signal weak cash returns and forensic balance-sheet risk.. With a beta of 1.0 and the stock sitting at $2.78 (52-wk range $1.32–$15.04), the easy multiple expansion is already priced in.